MET and Non-Small Cell Lung Cancer  (NSCLC) sign


Understand MET

MET alterations including

MET exon 14 skipping (METex14) are oncogenic alterations in NSCLC, and it’s important to know every patient's status.

Many different oncogenic alterations can contribute to the development of NSCLC.1
MET dysregulation drives oncogenic signaling in NSCLC.2
METex14 is an oncogenic alteration in NSCLC that is associated with poor prognosis.3-5

NSCLC, non-small cell lung cancer.


1. Yoda S, Dagogo-Jack I, Hata AN. Pharmacol Ther. 2019;193:20-30.
2. Kim JH, Kim HS, Kim BJ. J Cancer. 2018;9(10):1836-1845.
3. Drilon AD, Cappuzzo F, Ou SI, Camidge DR. J Thorac Oncol. 2017;12(1):15-26.
4. Awad MM, Leonardi GC, Kravets S, et al. Lung Cancer. 2019;133:96-102.
5. Tong JH, Yeung SF, Chan AWH, et al. Clin Cancer Res. 2016;22(12):3048-3056.


This is a global website and is intended for health care professionals. The information on this site is intended for educational purposes only and is not country-specific.


Use of website is governed by the Terms of Use and Privacy Policy.

Copyright © 2020 Novartis AG. All rights reserved.

10/19     G-CAP-1220183